Covid Vaccine Front-Runner Held Back By China-Canada Spat

The video discusses CanSino's journey in developing a COVID-19 vaccine, highlighting its initial success and subsequent challenges. Initially, CanSino was a promising candidate with backing from both Chinese and Western entities. However, its results were less promising compared to competitors like Moderna and Oxford AstraZeneca. Geopolitical tensions, particularly between China and Canada, further complicated its progress, delaying crucial phase three trials and impacting its global standing.

What made CanSino's COVID vaccine candidate initially appealing to investors?

• Its promising results compared to Moderna

• Its collaboration with the Chinese military and Western scientific establishments

• Its partnership with the Canadian government

• Its focus on domestic trials only

Which vaccine candidates showed more promising results than CanSino's?

• Sputnik V and Novavax

• Sinovac and Bharat Biotech

• Moderna and Oxford AstraZeneca

• Pfizer and Johnson & Johnson

What was the main reason CanSino's partnership with Canada became a liability?

• Geopolitical tensions between China and Canada

• Canada's refusal to conduct trials

• Poor vaccine efficacy in Canadian trials

• Lack of funding from the Canadian government

Why were CanSino's phase three trials in Canada halted?

• Technical issues with the vaccine

• Insufficient funding for the trials

• Beijing's refusal to approve the shipment of vaccines

• Lack of volunteers in Canada

What was the impact of the halted trials on CanSino's vaccine development?

• It accelerated their development process

• It had no impact on their timeline

• It put them behind other firms in the vaccine race

• It led to immediate approval in other countries